| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:FLT3-IN-14
CAS:2620551-45-1
Package:100mg/RMB 17500;25mg/RMB 10600;50mg/RMB 13800
|
Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- manufacturers
- FLT3-IN-14
-
- $2500.00 / 100mg
-
2025-04-29
- CAS:2620551-45-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- Basic information |
| Product Name: | Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- | | Synonyms: | Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]-;FLT3-IN-14 | | CAS: | 2620551-45-1 | | MF: | C25H24N6O2S | | MW: | 472.56 | | EINECS: | | | Product Categories: | | | Mol File: | 2620551-45-1.mol | ![Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- Structure](CAS/20210305/GIF/2620551-45-1.gif) |
| | Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- Chemical Properties |
| density | 1.48±0.1 g/cm3(Predicted) | | pka | 12.60±0.70(Predicted) |
| | Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- Usage And Synthesis |
| Uses | FLT3-IN-14 is a potent FLT3 inhibitor with IC50s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model[1]. | | in vivo | FLT3-IN-14 (1.0 and 3.0 mg/kg; IP; daily for 28 days) significantly reduces tumor growth in a dose-dependent manner without sign of toxicity[1]. | Animal Model: | NOD/SCID female mice (subcutaneously implanted MV4-11)[1] | | Dosage: | 1.0 and 3.0 mg/kg | | Administration: | IP; daily for 28 days | | Result: | Significantly reduced tumor growth by 44.1% and 55.2% at 1 and 3 mg/kg, respectively. |
| | References | [1] Cilibrasi V, Spanò V, Bortolozzi R, et al. Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations.?Eur J Med Chem. 2022 DOI:10.1016/j.ejmech.2022.114292 |
| | Urea, N-[4-(4,5-dihydro-2H-imidazo[2,1-b]pyrrolo[3,4-e]benzothiazol-8-yl)phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- Preparation Products And Raw materials |
|